The AACE/ACE, in contrast to the ADA, provides several monotherapy options that are recommended in the following order according to the strength of each recommendation: metformin, GLP-1 receptor agonist, SGLT-2 inhibitor, DPP-4 inhibitor, thiazolidinedione, -glucosidase inhibitor, and an insulin secretagogue (a sulfonylurea or meglitinide)
Novo was first in the market,got CMS Medicare approval with Narrow Pipeline of Drugs only on Weight loss & Diabetes (Front runner Semaglutide) Lilly has better Efficacy Drug(Tirzepatide & Pipeline drugs) for Wt loss/Diabetes,Longer IP Patent Runway till mid 2030s with better Growth Penetration With Wider Pipeline of Pharma drugs including Oncology/ Neurology/ Immunology/ Inflammation,Urology- Erectile Dysfunction,Osteoporosis in Men and Women and afford to run the price war with Novo and wipeout their Business Eli Lilly is winning hands down
Nutritional optimization: A well-balanced diet rich in lean protein, complex carbohydrates, healthy fats, vitamins, and minerals can support muscle growth, recovery, and overall health
He faces one count of interstate transport of stolen goods, for which the maximum penalty is 10 years in prison and a fine of $250,000
One possibility is that GLP-1R endocytosis is required for agonist uptake by the brain via hypothalamic tanycytes, as described for leptin 65
